Table 3.
Per-cycle dosimetry estimates obtained with three-, two-, and one-time-point methods (n = 279)
| Absorbed dose (Gy) | Correlation vs. 3TP (r)b | Relative error vs. 3TP (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biological decay | No biological decaya | Combined | |||||||||
| 3TPTM | 2TPM | 3TPTC | 2TPC | 3TP | 2TP | 1TPD3 | 2TP | 1TPD3 | 2TP | 1TPD3 | |
| Kidney | 4.6 [2.7–6.6] (1.6–10.5) |
4.7 [2.8–6.8] (1.6–11.1) |
2.5 | 2.6 | 4.6 [2.7–6.6] (1.6–10.5) |
4.7 [2.7–6.8] (1.6–11.1) |
4.8 [2.7–7.1] (1.4–11.6) |
0.997 | 0.990 | 2.0 [− 0.6–4.9] (− 3.4–16.0) |
5.8 [− 0.4–9.2] (− 37.7–17.0) |
| Bone marrowself | 0.26 [0.12–0.63] (0.05–2.08) |
0.25 [0.11–0.62] (0.04–2.18) |
0.36 [0.21–0.90] (0.17–3.84) |
0.34 [0.20–0.86] (0.16–3.88) |
0.27 [0.12–0.64] (0.05–3.84) |
0.25 [0.12–0.63] (0.04–3.88) |
0.22 [0.11–0.56] (0.04–2.41) |
0.996 | 0.774 | − 5.2 [− 11.4–0.6] (− 21.9–14.1) |
−10.0 [− 35.4–1.3] (− 43.3–17.0) |
| Bone marrowcross | 0.024 [0.013–0.061] (0.004–0.159) |
0.022 [0.011–0.060] (0.003–0.155) |
– | – | 0.024 [0.013–0.061] (0.004–0.159) |
0.022 [0.011–0.060] (0.003–0.155) |
0.022 [0.012–0.054] (0.003–0.122) |
0.998 | 0.990 | − 5.0 [− 12.6 to − 0.8] (− 29.2–10.0) |
−6.7 [− 16.5–1.3] (− 35.4–9.7) |
| Tumormaxc | 30.9 [7.5–70.8] (0.5–277.6) |
31.3 [7.8–71.9] (0.5–271.1) |
47.0 [12.1–81.0] (2.9–120.0) |
47.6 [7.4–82.6] (2.9–121.7) |
31.2 [7.4–74.1] (0.5–277.6) |
31.7 [7.6–76.0] (0.5–271.1) |
27.8 [6.8–61.4] (0.5–215.3) |
1.000 | 0.651 | 1.7 [− 0.4–3.9] (− 3.5–14.0) |
− 9.6 [− 30.4–8.0] (− 35.9–15.6) |
C constant, D3 day 3, M monoexponential, TC trapezoid-constant, TM trapezoid-monoexponential, TP time point(s)
Data is presented as median [interdecile range] (range)
Median injected activity was 7.7 (range, 0.7–32.4) GBq
aKidney, n = 1; BMself n = 30; BMcross n = 0; Tumormax n = 26
bSpearman’s correlation, P < 0.0001 in all cases
cn = 278